We are live on ! Find out more
SAM

Sectoral Asset Management Portfolio holdings

AUM $121M
1-Year Est. Return 73.47%
This Fund
S&P 500
This Quarter Est. Return
+2.22%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$121M
AUM Growth
-$4.02M
Cap. Flow
-$6.69M
Cap. Flow %
-5.54%
Top 10 Hldgs %
48.15%
Holding
84
New
10
Increased
18
Reduced
47
Closed
7

Top Buys

Rank Stock Value
1
IQV icon
IQVIA
IQV
+$1.62M
2
GILD icon
Gilead Sciences
GILD
+$1.35M
3
INSM icon
Insmed
INSM
+$1.3M
4
BMY icon
Bristol-Myers Squibb
BMY
+$1.23M
5
MDT icon
Medtronic
MDT
+$1.06M

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$1.4M
2
AMGN icon
Amgen
AMGN
+$1.38M
3
ABBV icon
AbbVie
ABBV
+$1.02M
4
CTNM
Contineum Therapeutics
CTNM
+$982K
5
LLY icon
Eli Lilly
LLY
+$935K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EVMN
1
Evommune Inc
EVMN
$437M
$13.5M 11.22%
589,005
– –
CTNM
2
Contineum Therapeutics
CTNM
$532M
$9.5M 7.87%
727,587
-73,200
-9% -$982K
SI
3
Shoulder Innovations Inc
SI
$448M
$6.25M 5.18%
430,407
-62,028
-13% -$863K
LLY icon
4
Eli Lilly
LLY
$1.05T
$5.84M 4.84%
6,354
-922
-13% -$935K
JNJ icon
5
Johnson & Johnson
JNJ
$609B
$4.45M 3.69%
18,218
-2,082
-10% -$485K
GILD icon
6
Gilead Sciences
GILD
$167B
$4.13M 3.42%
27,490
+9,605
+54% +$1.35M
UNH icon
7
UnitedHealth
UNH
$387B
$4.05M 3.35%
14,957
+1,362
+10% +$406K
AMGN icon
8
Amgen
AMGN
$198B
$3.51M 2.91%
9,210
-3,860
-30% -$1.38M
VRTX icon
9
Vertex Pharmaceuticals
VRTX
$123B
$3.46M 2.86%
7,007
-998
-12% -$465K
INSM icon
10
Insmed
INSM
$23.5B
$3.38M 2.8%
19,668
+8,486
+76% +$1.3M
ARGX icon
11
argenx
ARGX
$53.8B
$2.74M 2.27%
3,564
+670
+23% +$524K
ABBV icon
12
AbbVie
ABBV
$450B
$2.65M 2.2%
12,200
-4,600
-27% -$1.02M
ABT icon
13
Abbott
ABT
$175B
$2.63M 2.18%
25,578
+2,080
+9% +$235K
MRK icon
14
Merck
MRK
$315B
$2.58M 2.14%
21,480
+80
+0.4% +$9.24K
REGN icon
15
Regeneron Pharmaceuticals
REGN
$70.9B
$2.48M 2.06%
2,919
-796
-21% -$609K
ISRG icon
16
Intuitive Surgical
ISRG
$122B
$2.42M 2%
5,250
+400
+8% +$202K
BSX icon
17
Boston Scientific
BSX
$65.4B
$2.18M 1.81%
34,780
+7,154
+26% +$572K
BNTX icon
18
BioNTech
BNTX
$23.1B
$2.05M 1.69%
22,164
+4,946
+29% +$508K
SYK icon
19
Stryker
SYK
$123B
$1.93M 1.6%
5,874
-676
-10% -$243K
DHR icon
20
Danaher
DHR
$144B
$1.82M 1.51%
9,597
-978
-9% -$208K
TMO icon
21
Thermo Fisher Scientific
TMO
$198B
$1.72M 1.43%
3,508
-392
-10% -$213K
DXCM icon
22
DexCom
DXCM
$29.6B
$1.46M 1.21%
23,231
-5,469
-19% -$381K
IQV icon
23
IQVIA
IQV
$34.4B
$1.42M 1.17%
+8,307
New +$1.62M
SMMT icon
24
Summit Therapeutics
SMMT
$10.7B
$1.4M 1.16%
69,615
-10,010
-13% -$162K
EW icon
25
Edwards Lifesciences
EW
$49.4B
$1.39M 1.15%
17,338
+88
+0.5% +$7.25K
1
2 3 4

Similar funds

RIP
Reliant Investment Partners Pinehurst, North Carolina $121M AUM 34.77% 1-Year Est. Return
CCM
Chicago Capital Management Chicago, Illinois $121M AUM 74.36% 1-Year Est. Return
LFWA
LiftPoint Family Wealth Advisors Far Hills, New Jersey $121M AUM
FWA
Fulcrum Wealth Advisors Bellevue, Washington $121M AUM
CF
Conquis Financial Milbrae, California $121M AUM 16.22% 1-Year Est. Return
WIM
Wiregrass Investment Management Thomasville, Georgia $121M AUM
MW
Merited Wealth North Bay Village, Florida $121M AUM
AFC
Avise Financial Cooperative Los Angeles, California $121M AUM

Sectoral Asset Management's Q1 2026 Portfolio in Review

As of Q1 2026, Sectoral Asset Management held 84 positions worth $121M, down 3.2% from $125M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Sectoral Asset Management withdrew a net $6.69M in Q1 2026, closing 7 positions and reducing 47 holdings. Its most notable exit was AstraZeneca, an estimated $1.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Sectoral Asset Management opened a new position in IQVIA worth $1.42M.

  • Sectoral Asset Management's largest Q1 2026 buy was IQVIA: 8,307 shares worth $1.42M.
  • Sectoral Asset Management added most to Gilead Sciences in Q1 2026, an estimated $1.35M increase.
  • Sectoral Asset Management's biggest Q1 2026 reduction was Amgen, cutting an estimated $1.38M.
  • Sectoral Asset Management fully exited AstraZeneca in Q1 2026, selling an estimated $1.4M.
  • Sectoral Asset Management's ten largest holdings make up 48% of its $121M portfolio in Q1 2026.
  • Sectoral Asset Management opened 10 new positions and closed 7 in Q1 2026.
  • Sectoral Asset Management's portfolio value fell 3.2% quarter-over-quarter to $121M.

Based on Sectoral Asset Management's 13F filing for Q1 2026, filed 15 May 2026.